Long-Acting PrEP Status Update
Updated as of July 2026
This dashboard provides a timely snapshot on the progress of accelerating access to long-acting PrEP products. The graphics featured here track regulatory approvals, volumes, ongoing and planned implementation science studies, and non-profit prices for approved longer-acting PrEP products, including injectable cabotegravir, injectable lenacapavir, and the dapivirine vaginal ring. The dashboard is updated quarterly by AVAC, Secretariat to the Coalition to Accelerate Access to Long-Acting PrEP.
The Pathway to Access and Impact
This graphic outlines the critical steps for rolling out long-acting injectable PrEP products.
Download the static version of this graphic or hover over the graphic and click the three dots on the upper right to access full screen mode.
Long-Acting PrEP Generic License Coverage
